JW (Cayman) Therapeutics Co. Ltd

HKSE 2126.HK

JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) for the year ending December 31, 2023: 411,530,000

JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) is 411,530,000 for the year ending December 31, 2023, a 0.35% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) for the year ending December 31, 2022 was 410,093,000, a 2.59% change year over year.
JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) for the year ending December 31, 2021 was 399,749,000, a 203.07% change year over year.
JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) for the year ending December 31, 2020 was 131,901,000, a 102.92% change year over year.
JW (Cayman) Therapeutics Co. Ltd Shares (Diluted, Weighted) for the year ending December 31, 2019 was 65,000,000, a -82.72% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

HKSE: 2126.HK

JW (Cayman) Therapeutics Co. Ltd

CEO	Mr. Min Liu
IPO Date	Nov. 3, 2020
Location	China
Headquarters	Building B
Employees	323
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Key trends

Past 5 years